ATNM - Actinium Pharmaceuticals, Inc.
NYSE
->
Healthcare
->
Biotechnology
New York,
United States
Type: Equity
ATNM price evolution
ATNM
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $79.52 | $87.07 | $85.37 | $78.26 |
| Long term investments | ||||
| Property, plant & equipment | $2.27 | $2.48 | $2.66 | $2.87 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $82.11 | $89.86 | $88.35 | $81.44 |
| Current liabilities | ||||
| Accounts payable | $7.2 | $9.18 | $7.51 | $7.95 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $7.75 | $9.73 | $8.06 | $8.49 |
| Long term debt | $0.01 | $0.01 | $0.02 | $0.02 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $43.91 | $46.03 | $44.49 | $45.07 |
| Shareholders' equity | ||||
| Retained earnings | -$369.17 | -$357.61 | -$346.25 | -$337.58 |
| Other shareholder equity | ||||
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 30 Jan 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $63.61 | |||
| Short term investments | ||||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $78.26 | $110.94 | $79.75 | $64.92 |
| Long term investments | ||||
| Property, plant & equipment | $2.87 | $2.95 | $0.64 | $0.31 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $1.47 | |||
| Total investments | ||||
| Total assets | $81.44 | $114.19 | $80.39 | $66.4 |
| Current liabilities | ||||
| Accounts payable | $7.95 | $10.13 | $5.54 | $4.34 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $8.49 | $10.63 | $6.84 | $4.77 |
| Long term debt | $0.02 | $0 | $0.07 | |
| Total noncurrent liabilities | $0.31 | |||
| Total debt | ||||
| Total liabilities | $45.07 | $47.71 | $6.84 | $5.08 |
| Shareholders' equity | ||||
| Retained earnings | -$337.58 | -$288.76 | -$255.75 | -$230.97 |
| Other shareholder equity | ||||
| Total shareholder equity | ||||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.08 | |||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $12.6 | $12.42 | $9.6 | $10.42 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | $1.03 | $1.06 | $0.93 | $1.02 |
| Net income | ||||
| Net income | -$11.57 | -$11.35 | -$8.67 | -$9.32 |
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 30 Jan 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.08 | $1.03 | ||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $52 | $35.13 | $22.39 | |
| Operating income | -$22.39 | |||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | $3.1 | $1.09 | ||
| Net income | ||||
| Net income | -$48.82 | -$33.02 | -$22.21 | |
| Income (for common shares) | ||||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$0.01 | -$0.01 | -$0.01 | -$0.15 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $29.32 | $24.72 | $14.77 | $14.87 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $1.99 | $9.37 | $7.38 | -$32.62 |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 30 Jan 2021 |
|---|---|---|---|---|
| Net income | -$22.21 | |||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$21.62 | |||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$0.15 | -$0.37 | -$0.13 | -$0.25 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $14.87 | $23.11 | $35.22 | $76.18 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$32.62 | $31.39 | $14.22 | $54.31 |
News
Fundamentals
| Market cap | $52.10M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 31.20M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$40.91M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | -1.27 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$1.31 |
|---|---|
| ROA | -47.89% |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 10.25 |
| Quick ratio | N/A |